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Abstract
Objective: To describe the prevalence of the L76V protease inhibitors resistance-associated mutation (PI-RAM) in relation
with patients’ characteristics and protease genotypic background in HIV-1 B- and ‘‘non-B’’-infected patients.
Methods: Frequency of the L76V mutation between 1998 and 2010 was surveyed in the laboratory database of 3 clinical
centers. Major PI-RAMs were identified according to the IAS-USA list. Fisher’s and Wilcoxon tests were used to compare
variables.
Results: Among the overall 29,643 sequences analyzed, the prevalence of L76V was 1.50%, while was 5.42% in PI-resistant
viruses. Since 2008 the prevalence of L76V was higher in ‘‘non-B’’-infected than in B-infected patients each year. Median
time since diagnosis of HIV-1 infection and median time under antiretroviral-based regimen were both shorter in ‘‘non-B’’-
than in B-infected patients (8 vs 11 years, P,0.0001; and 7 vs 8 years, P= 0.004). In addition, ‘‘non-B’’-infected patients had
been pre-exposed to a lower number of PI (2 vs 3, P= 0.016). The L76V was also associated with a lower number of major PI-
RAMs in ‘‘non-B’’ vs B samples (3 vs 4, P = 0.0001), and thus it was more frequent found as single major PI-RAM in ‘‘non-B’’ vs
B subtype (10% vs 2%, P = 0.014).
Conclusions: We showed an impact of viral subtype on the selection of the L76V major PI-RAM with a higher prevalence in
‘‘non-B’’ subtypes observed since 2008. In addition, in ‘‘non-B’’-infected patients this mutation appeared more rapidly and
was associated with less PI-RAM.
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Introduction
The antiretroviral drug class of protease inhibitors (PI) is known
to have a high genetic barrier to resistance [1]. The recent large
clinical trials assessing the efficacy of boosted PI-containing
regimen in antiretroviral-naı¨ve patients showed a very low rate
of selection of PI resistance-associated mutations (RAM) in case of
virological failure [2,3]. However, a novel resistance pathway
involving the protease mutation L76V was recently described both
in antiretroviral-naı¨ve patients [4,5] and in antiretroviral-experi-
enced patients [6–9]. The L76V is a drug resistance mutation
associated with resistance to lopinavir, darunavir, fosamprenavir
and indinavir [4–5,10]. In addition, the L76V is associated with an
in vitro hypersusceptibility to saquinavir, atazanavir, and tipranavir
[11,12].
The prevalence of the L76V mutation in PI-resistant viruses was
found about 3.3% in two large databases of clinical sequences
[5,10], with no viral subtype sub-analysis. Some studies reported
a high prevalence of L76V in ‘‘non-B’’ subtypes, particularly in the
CRF02_AG recombinant [4,8]. Firstly, in the MONARK study,
assessing lopinavir monotherapy in antiretroviral-naı¨ve patients,
the prevalence of the L76V in case of virological failure was 9.4%
in this study and all patients displaying L76V-mutated viruses at
failure were infected with CRF02_AG recombinant [4]. In a study
assessing genotypic resistance profiles in 57 patients living in
Cameroon, all infected with HIV-1 ‘‘non-B’’ subtypes, the
prevalence of the L76V was 8.8% [8]. However, few data are
available on the impact of the viral subtype on the selection of the
L76V mutation.
The aim of the study was to describe the L76V protease
mutation in term of prevalence, patients characteristics, and PI
RAM clustering with the L76V mutation in the context of HIV-1
B subtype and HIV-1 ‘‘non-B‘‘ subtypes.
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Patients and Methods
Database Analysis
Frequency of the L76V mutation was surveyed in the clinical
laboratory database of 2 clinical centers in Paris, France (Pitie´-
Salpeˆtrie`re and Bichat-Claude Bernard Hospitals) and 1 in Rome,
Italy (University of Rome ‘‘Tor Vergata’’). Sequences included in
the databases of the 3 centers resulted from all the genotypic
resistance tests performed in clinical routine requested by the
physician during patients’ follow up between 1998 and 2010. This
included as well antiretroviral-naı¨ve as antiretroviral-experienced
patients. No significant difference in the nature of ARV-based
treatment prescribed was observed according to the center.
Similar demographic characteristics were observed among the
patients followed in the 3 centers of the study (data not shown),
except for the proportion of HIV-‘‘non-B’’-infected patients that is
lower in the Roman centre (18%) than in the Parisian centers
(42% and 51%). In our study, samples with at least one of the
major PI RAM of the IAS-USA list as follows: D30N, V32I,
M46I/L, I47A/V, G48V, I50L/V, I54L/M, Q58E, T74P, L76V,
V82A/F/L/T/S, N83D, I84V, N88S, L90M were considered as
PI-resistant issued from PI-experienced patients [13]. In the case
of multiple samples from the same patient we only taking into
account the first chronological sample harboring the L76V
mutation.
Genotypic Resistance Tests
Population-based sequencing of protease and reverse transcrip-
tase were performed in the 2 Parisian centers using an in-house
PCR assay according to the complete sequencing procedures and
primers sequences described at www.hivfrenchresistance.org. The
Roma center used a commercial assay (ViroSeqH HIV-1
genotyping system, Celera Diagnostics, Alameda, Ca), as pre-
viously described [14]. Resistance mutations and major PI RAMs
were identified according to the IAS-USA list [13].
HIV-1 Subtyping
HIV-1 subtype was determined by phylogenetic analyses, by
estimating the relationships among RT sequences and reference
sequences of HIV-1 genetic subtypes and circulating recombinant
forms (CRF) obtained from the Los Alamos Database (http://hiv-
web.lanl.gov). Phylogenetic trees were inferred using the neigh-
bour-joining method and two Kimura parameters with 1000
bootstrap values.
Mutations Covariation Analysis
The association of the L76V mutation with other PI RAM was
assessed in a subset of 1,956 subtype B and 481 subtypes ‘‘non-B’’
sequences obtained from patients failing their last PI-based
regimen, with a full-length protease sequence available at the
time of failure, including sequences without L76V mutation.
To identify significant patterns of pairwise correlations between
the L76V mutation and specific PI RAM observed in isolates from
PI-experienced patients, we calculated the binomial correlation
coefficient (phi) and its statistical significance for each pair of
mutations. Average linkage hierarchical agglomerative cluster
analysis was performed to investigate if the protease mutations
pairwise associated with the L76V mutation raised in specific
evolutionary pathways, as previously described [15].
Statistical Analysis
To compare variables between HIV-1 B- and ‘‘non-B’’-infected
patients the Wilcoxon test and the Fisher exact test were used with
a P-value threshold .0.002 (Bonferroni correction). All tests were
two-sided at the 0.05 significance level. Analyses were performed
with StatEL statistical software (StatEL Base, www.adscience.eu).
Results
Prevalence of L76V Mutation Over Time
A number of 29,643 sequences issued from clinical samples
collected between 1998 and 2010 were available in the database.
Among them, 24,604 sequences are issued from antiretroviral-
treated patients (83%) and 19,861 sequences are HIV subtype B
(67%). Among the 29,643 sequences, 446 displayed the L76V
mutation in protease, leading to an overall prevalence of 1.50%.
138 out of the 446 L76V-mutated sequences are HIV-1 subtype
‘‘non-B’’ (31%).
When regarding the prevalence of the L76V mutation among
the PI-resistant viruses, containing at least one major PI RAM, it
was found at 5.42% (430/7,934).
In our database, a similar prevalence of the L76V mutation was
observed among B- and ‘‘non-B’’-infected patients until 2008
(Figure 1). Since 2008 the prevalence of L76V was higher in ‘‘non-
B’’-infected than in B-infected patients each year (P=0.02 in
2008, P=0.006 in 2009; and P=0.001 in 2010). In our database
the proportion of ‘‘non-B’’ subtypes increased from 27% to 41%
between 2003 and 2010.
Demographic, Therapeutic, and Virological
Characteristics of Patients Displaying L76V-mutated
Viruses
Regarding the 446 samples with L76V mutation in PI-
experienced patients, known clinical and therapeutic history for
further analyzes were available in 179 patients. Among them 118
(66%) were infected with HIV-1 subtype B and 61 (34%) with
HIV-1 ‘‘non-B‘‘ subtypes. The CRF02_AG recombinant form was
the most prevalent ‘‘non-B’’ subtype found in 29 samples (47%).
The distribution of the remaining HIV-1 ‘‘non-B’’ subtypes was as
follows: subtype A (n=6, 10%), D (n=6, 10%), F (n=4, 6%), G
(n=4, 6%), CRF06_cpx (n=2, 3%), CRF11_cpx (n=1, 2%),
CRF12_BF (n=1, 2%), C (n=1, 2%), H (n=1, 2%), and 6
samples with undetermined subtype.
At time of the first detection of the L76V mutation, median time
since HIV infection diagnosis and median time under antiretro-
viral-based regimen were both shorter in ‘‘non-B’’ patients
compared with subtype B patients (8 vs 11 years, P,0.0001; and
7 vs 8 years, P=0.004, respectively) (Table 1). Similar results were
obtained if we compared patients infected with HIV-1 subtype B
samples to those infected with the CRF02_AG recombinant (data
not shown).
At the time of first detection of the L76V mutation, there was no
significant difference in the nature of PI received between patients
infected with B and ‘‘non-B’’ subtypes (Table 1). However,
patients infected with B subtype received more frequently
lopinavir than patients infected with CRF02_AG (62 vs 41%,
P=0.04).
We also assessed the PI pre-exposure showing that patients
infected with ‘‘non-B’’ subtypes received a lower number of PI
before the selection of the L76V mutation than those infected with
B subtype (2 vs 3, P=0.016), although the duration of PI-based
regimen was similar in the 2 groups of patients. There was no
difference in the nature of the PI previously received except for
indinavir, more frequently received by subtype B patients than by
‘‘non-B’’ patients (82 vs 62%, P=0.041). Similar results were
obtained if we compared patients infected with HIV-1 subtype B
samples to those infected with the CRF02_AG recombinant.
L76V Mutation and HIV-1 Subtypes
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Figure 1. Prevalence of the L76V mutation between 1998 and 2010 in a database containing 29,643 sequences issued from clinical
samples with any antiretroviral drug resistance.
doi:10.1371/journal.pone.0054381.g001
Table 1. Population characteristics of patients infected with HIV-1 subtype B and HIV-1 ‘‘non-B’’ subtypes with L76V protease
mutation.
Populations parameter*
Patients infected with HIV-1
subtype B (n=118)
Patients infected with HIV-1
subtype ‘‘non-B’’ (n=61) P-value
Age (years) 42 (37–48) 41 (36–48) 0.2
Gender n(%) women 16 (14) 29 (48) 0.00001
Time since HIV infection diagnosis (years) 11 (8–15) 8 (6–11) 0.00001
Time since initial ARV-based regimen (years) 8 (6–11) 7 (4–9) 0.004
HIV-1 RNA level (log10 copies/mL) 4.31 (3.63–5.12) 4.13 (3.27–4.94) 0.71
PI received at time of the L76V initial detection n(%)
lopinavir 73 (62) 34 (56) 0.39
indinavir 14 (12) 10 (16) 0.41
amprenavir/fosamprenavir 18 (15) 5 (8) 0.17
saquinavir 8 (7) 7 (11) 0.29
darunavir 8 (7) 5 (8) 0.77
nelfinavir 4 (3) 0 (0) 0.30
atazanavir 0 (0) 0 (0) 1.00
tipranavir 0 (0) 0 (0) 1.00
Number of PI received during therapeutic history 3 (2–4) 2 (1–3) 0.016
Duration of PI-based regimens during therapeutic history (months) 61 (43–83) 59 (33–81) 0.053
Dual PI regimen n(%) 23 (19) 15 (25) 0.36
PI previously received during therapeutic history n(%)
lopinavir 90 (76) 46 (75) 0.82
indinavir 97 (82) 38 (62) 0.041
amprenavir/fosamprenavir 40 (34) 17 (28) 0.39
saquinavir 54 (46) 19 (31) 0.061
darunavir 7 (6) 5 (8) 0.55
nelfinavir 49 (41) 19 (31) 0.16
atazanavir 5 (4) 0 (0) 0.17
tipranavir 3 (3) 3 (5) 0.41
*Continuous variables were expressed as median and interquartile range (IQR) and categorical variables were expressed as numbers and percentages.
95% CI: 95% Confidence Interval; ARV: antiretroviral; PI: protease inhibitor.
doi:10.1371/journal.pone.0054381.t001
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Among the 179 patients of the study, 41 (23%) displayed plasma
virus with L76V, although they never received lopinavir. Most of
these patients (n=38, 93%) received indinavir in their therapeutic
history. There was no difference in the proportion, in the
demographic characteristics, and in the pre-therapeutic history
of these patients depending of the viral subtype.
Protease Mutation Patterns of L76V-mutated Viruses
among HIV-1 B and ‘‘non-B’’ Subtypes
The number of major PI RAMs associated with L76V mutation
was lower in ‘‘non-B’’ samples than in subtype B samples (3 vs 4,
P=0.0001). Only 8 samples (8/179, 4.5%) were found with L76V
as the sole PI RAM, with a higher frequency in ‘‘non-B’’ than in
subtype B samples (10% vs 2%, P=0.014). Among the 8 patients
exhibiting plasma virus with the single L76V mutation, 5 were
receiving a lopinavir-based therapy as first line regimen, and half
were infected with CRF02_AG (n=4).
The prevalence of major PI RAMs found with the L76V is
depicted in Figure 2. The most prevalent PI RAM detected with
L76V was the M46I/L, both in subtype B and ‘‘non-B’’ samples,
found in 92 and 82% of cases, respectively. Then, the most
prevalent mutation found with L76V was the V82A/F/L/T/S
(52%) in subtype B samples and I84V (36%) in ‘‘non-B’’ samples.
Significant differences in the prevalence of PI RAMs detected with
the L76V between subtype B and ‘‘non-B’’ samples were found at
4 positions with a higher prevalence of the V32I, M46I/L, V82A/
F/L/T/S and L90M mutations in subtype B than in ‘‘non-B’’
samples: 10 vs 0%, P=0.04; 92 vs 82%, P=0.036; 52 vs 26%,
P=0.0011; and 42 vs 18%, P=0.002, respectively.
Analysis of Covariation of L76V among Protease
Mutations
Among subtype B samples, the major PI RAM significantly
correlating as pairs with L76V were: M46I, I54L/M, Q58E,
V82F, I84V, and L90M. The strongest associations were observed
with the M46I (covariation frequency 25.9%, phi = 0.39), and
I84V major PI RAM (covariation frequency 28.4%, phi = 0.28).
The L90M mutation was co-present with the L76V in 49 (11.6%)
patients (phi = 0.12). Regarding secondary PI RAM the strongest
associations were found with the mutations K55R (covariation
frequency 36.4%, phi = 0.32), I54V (covariation frequency 23.3%,
phi = 0.27), and L33F (covariation frequency 27.2%, phi = 0.27).
Similar pairwise correlations were observed in ‘‘non-B’’ sequences
(phi .0.10, P,0.0001), with an additional correlation with the
I47V major PI RAM (covariation frequency 72.8%, phi = 0.27).
Furthermore, we performed average linkage hierarchical
agglomerative cluster analysis to investigate if the protease
mutations pairwise associated with L76V raised in specific
evolutionary pathways. In subtype B samples, the strongly
correlated pairs of mutations L76V and M46I clustered along
with the I84V and K55R mutations. This cluster was linked to
L24I, I54V, and V82A mutations. As a whole, this cluster was
highly significant (bootstrap value = 0.78) (Figure 3A).
Likewise, this cluster was confirmed also in HIV-1 ‘‘non-B’’
sequences, where the major PI RAM L76V, M46I, I54L and I84V
grouped together with the secondary one A71V (bootstrap
value = 0.86). Again, the topology of the dendrogram showed
the strong association between L76V and M46I (bootstrap
value = 0.95) (Figure 3B).
Virological Response to the Subsequent Antiretroviral-
based Regimen
Virological response to the subsequent antiretroviral-based
regimen was assessable in 108 patients of the study at month 3
(M3) and in 98 patients at month 6 (M6). Overall, 20% and 28%
of patients displayed HIV-1 RNA below 50 copies/mL at M3 and
M6, respectively. The highest rate of virological success was
observed with darunavir-based regimen showing 50% (n=13) of
patients in success at M3 and 64% (n=14) at M6. At M6, a higher
rate of virological success was observed in patients infected with
HIV-1 ‘‘non-B’’ than in those infected with B subtype (50% vs
26%, P=0.03).
Discussion
In the present study based on 179 patients, including 61 ‘‘non-
B’’-infected patients, exhibiting plasma virus with the L76V major
drug resistance mutation in the protease region we showed that the
Figure 2. Proportion of protease inhibitors resistance-associated mutations with the L76V mutation in HIV-1 subtype B samples
and in HIV-1 ‘‘non-B’’ samples. P-values are indicated only if significant.
doi:10.1371/journal.pone.0054381.g002
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Figure 3. Dendrograms obtained from average linkage hierarchical agglomerative clustering, showing significant clusters of L76V
protease inhibitors resistance mutations among B subtype sequences (A), and among ‘‘non-B’’ subtype sequences (B). The length of
branches reflects distances between mutations in the original distance matrix. Bootstrap values, indicating the significance of clusters, are reported in
the boxes.
doi:10.1371/journal.pone.0054381.g003
L76V Mutation and HIV-1 Subtypes
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selection of this mutation appeared earlier in infection history,
earlier in therapeutic history and occurred in virus harboring
a lower number of major PI resistance mutations in ‘‘non-B’’-
infected patients compared to subtype B-infected patients.
Some limitations of our study might be that ‘‘non-B’’ subtypes
constitute a heterogeneous group with low number of sequences
available for each subtype preventing subtypes specific analyzes
except for CRF02_AG.
Overall in our database containing more than 29,000
sequences, we described a prevalence of the L76V mutation of
1.50% in all sequences and of 3.94% in viruses issued from PI-
experienced patients. This prevalence is similar to that described
in previous studies reporting 1.16% of L76V in the study of
Nijhuis et al. in all viruses and 3.4% and 3.2% in the studies of
Nijhuis et al. and Norton et al., respectively, in PI-resistant viruses.
In our study, the overall prevalence of L76V tends to decrease
during the study period, with no statistical significance. The
overtime decrease of prevalence has been recently also described
for the M184I/V and K103 resistance mutations [16]. The more
effective and better tolerated antiretroviral-based regimens likely
contribute to the decreased population trends of drug resistance.
In the present study we described that the prevalence of L76V
since 2008 is significantly higher in ‘‘non-B’’-infected patients than
in subtype B-infected patients. To our knowledge, this is the first
time that a differential prevalence of the L76V depending of the
viral subtype was described.
In our study a shorter time since HIV diagnosis, a shorter time
under antiretroviral-based therapy, and a lower number of PI in
the therapeutic history were all significantly observed in ’’non-B’’-
infected patients when compared to B-infected patients exhibiting
L76V-mutated viruses. In the study of Champenois et al. de-
mographic and clinical data were similar between patients
harboring L76V-mutated viruses and those with wild-type residue
at position 76, no viral subtype analysis was performed [17].
We also showed that the L76V mutation was associated with
a lower number of major PI RAMs in ‘‘non-B’’ than in subtype B
sequences. We did not analyze minor PI RAMs, as these positions
might be polymorphic in ‘‘non-B’’ subtypes. Moreover, no
reference lists of mutations are available for ‘‘non-B’’ subtypes.
The most prevalent PI RAM detected with L76V was the M46I
mutation, whatever the viral subtype, may be due to the use of
indinavir. Interestingly, a higher prevalence of virus exhibiting the
L76V mutation as single major PI RAM was observed in ‘‘non-B’’
sequences than in B sequences (10% vs 2%, respectively). In the
database assessed by Young et al., the prevalence of L76V as
single PI RAM was rare, found in 0.04% of the samples [10].
Several hypotheses may explain this apparent easier selection of
the L76V mutation in the context of ‘‘non-B’’ subtypes. Firstly, the
genetic barrier, defined as the number of viral mutations required
to overcome the drug-selective pressure, is one of the important
factors in the development of drug resistance. Differences have
been previously observed in the genetic barrier to resistance in
mutations associated with resistance to non nucleoside reverse
transcriptase inhibitors (NNRTI) for the A98S and V106M
mutations between HIV-1 B and C subtypes [18,19], or in
mutations associated with resistance to integrase inhibitors
between B and CRF02_AG subtypes [20]. When regarding the
position 76 of the protease at the nucleotidic level, we observed
a high degree of conservation suggesting a similar genetic barrier
between B and CRF02_AG sequences (data not shown). These
findings suggest that there is no lower genetic barrier to acquire
the L76V in CRF02_AG than in subtype B, with a change from T
to G in both cases.
Secondly, HIV-1 ‘‘non-B’’ subtypes protease sequences exhibit
several natural polymorphisms, and some are associated with
resistance PI drug class. This specific genotypic background of
‘‘non-B’’ subtypes protease may have a possible role in a more
rapid selection of the L76V mutation. The covariation analysis we
performed in our study showed that the L76V mutation clustered
with the major PI RAM M46I as described in previous studies
both in B and non-B viruses [4–5,8]. In our study, the covariation
analysis did not allow to evidence different clustering of the L76V
PI RAM with protease polymorphisms or other PI RAM
according to the viral subtype. These findings suggest that the
more rapid selection of the L76V observed in ‘‘non-B’’ subtypes
might not be explained by an association of the L76V with
a specific protease polymorphism or PI RAM in ‘‘non-B’’ subtype.
Previous studies demonstrated the role of gag cleavage sites
mutations in the development of resistance to PI [21–23]. In the
MONARK study, assessing the PI monotherapy strategy in
antiretroviral-naı¨ve patients, ‘‘non-B’’ subtypes isolates were
significantly more likely to harbor mutations in gag cleavage sites
at baseline than B subtype isolates (P,0.0001) [24]. In our study,
one hypothesis might be that the presence of pre-therapeutic gag
polymorphisms could favor the selection of the L76V mutation.
This hypothesis needs further investigation.
Regarding the virological response to subsequent regimen, the
highest rate of virological success (64%) was observed with
darunavir-based regimen. In our study we showed a higher rate
of virological success in the subsequent regimen in patients
infected with HIV-1 ‘‘non-B’’ than in those infected with B
subtype, we can make the hypothesis that it could be related to the
lower number of PI RAMs observed in ‘‘non-B’’ infected patients.
However, this part of the study have several limitations, as the
limited number of patients and the fact that the study reports on
different periods during which optimal antiretroviral-based regi-
mens were not always used.
In conclusion, in this study assessing the prevalence of L76V PI
RAM in ‘‘non-B’’- and B-infected patients, we showed that the
viral subtype could have an impact on the selection of this
mutation. For the first time a higher prevalence of the L76V
mutation in ‘‘non-B’’- than in B-infected patients was observed
since 2008. In addition, the L76V mutation appeared more
rapidly and was associated with less PI-RAM in ‘‘non-B’’ subtypes
than in B subtype. Further structural and/or in vitro experiments
are needed to better explain this phenomenon. In addition, further
studies based on immuno-virological outcome of HIV-1 ‘‘non-B’’-
infected patients receiving PI-based regimen, especially in re-
source-limited settings, might help to assess the clinical implica-
tions of the presence of the L76V mutation.
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